Emmaus Life Sciences Files 8-K on Director/Officer Changes
Ticker: EMMA · Form: 8-K · Filed: Dec 19, 2025 · CIK: 822370
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: EMMA
TL;DR
Emmaus Life Sciences (EMMA) filed an 8-K detailing director/officer changes and financial statements.
AI Summary
Emmaus Life Sciences, Inc. filed an 8-K on December 19, 2025, reporting on events as of December 15, 2025. The filing covers the departure of directors, election of directors, appointment of officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant changes in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with the filing of financial statements, can signal shifts in company strategy or financial health, warranting closer investor scrutiny.
Key Players & Entities
- Emmaus Life Sciences, Inc. (company) — Registrant
- December 15, 2025 (date) — Earliest event reported
- December 19, 2025 (date) — Date of report
- MYnd Analytics, Inc. (company) — Former company name
- CNS RESPONSE, INC. (company) — Former company name
- STRATIVATION, INC. (company) — Former company name
FAQ
What specific changes were made regarding directors and officers?
The filing indicates the departure of directors, election of directors, and appointment of certain officers, along with details on compensatory arrangements for these officers.
What is the effective date of the events reported in this 8-K?
The earliest event reported is dated December 15, 2025.
When was this 8-K filing submitted to the SEC?
The filing was submitted on December 19, 2025.
What are the previous names of Emmaus Life Sciences, Inc.?
The company was formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC.
What items are covered under the 'Item Information' section of this filing?
The filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2025-12-19 16:05:38
Filing Documents
- ea0270178-8k_emmaus.htm (8-K) — 24KB
- 0001213900-25-123836.txt ( ) — 180KB
- emma-20251215.xsd (EX-101.SCH) — 3KB
- emma-20251215_lab.xml (EX-101.LAB) — 33KB
- emma-20251215_pre.xml (EX-101.PRE) — 22KB
- ea0270178-8k_emmaus_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the inline XBRL Document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2025 EMMAUS LIFE SCIENCES, INC. By: /s/ WILLIS LEE Name: Willis Lee Title: Chairman and Chief Executive Officer 2